The Carigent drug delivery platform allows for controlled release of therapeutic agents, targeting of therapy to a particular physiological site, tethering of surface ligands, and the ability to combine multiple agents into one vehicle made primarily from FDA approved materials.  The technology is unique as it combines well-characterized, safe materials with a novel method of adhering a high density of ligands to the surface which allow:

   §  incredible flexibility in targeting the drug delivery system to organs and diseases,

   §  combining imaging agents with drug, and/or

   §  extending circulation times.

We are aggressively pursuing a comprehensive product pipeline in multiple therapeutic areas including cancer treatment, antibody therapeutics, and siRNA delivery both internally and in collaboration with pharmaceutical and biotechnology industry leaders.